Changeset 1502 for qrda/C0Q/trunk/kids/C0Q*1.0*3.DONTUSE
- Timestamp:
- Aug 3, 2012, 2:09:49 PM (12 years ago)
- File:
-
- 1 edited
-
qrda/C0Q/trunk/kids/C0Q*1.0*3.DONTUSE (modified) (36 diffs)
Legend:
- Unmodified
- Added
- Removed
-
qrda/C0Q/trunk/kids/C0Q*1.0*3.DONTUSE
r1497 r1502 1 KIDS Distribution saved on Jul 27, 2012@15:36:382 SDFGHJKLXCVBNM,WERTYUI 1 KIDS Distribution saved on Aug 03, 2012@10:26:28 2 DFGHJKL 3 3 **KIDS**:C0Q*1.0*3^ 4 4 … … 6 6 C0Q*1.0*3 7 7 "BLD",7936,0) 8 C0Q*1.0*3^QUALITY MEASURES^0^3120 727^y8 C0Q*1.0*3^QUALITY MEASURES^0^3120803^y 9 9 "BLD",7936,1,0) 10 10 ^^5^5^3120713^ … … 28 28 29 29 "BLD",7936,6.3) 30 8 30 9 31 31 "BLD",7936,"ABPKG") 32 32 n … … 125 125 "BLD",7936,"REQB","B","QUALITY MEASURES 1.0",2) 126 126 127 "DATA",1130580001.101,1,0)128 M1^^^2.16.840.1.113883.3.249.11.2129 "DATA",1130580001.101,1,1)130 CMS Measure #1: Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus131 "DATA",1130580001.101,1,4)132 PQRI-1133 "DATA",1130580001.101,1,5)134 Hemoglobin A1c Poor Control in Diabetes Mellitus135 "DATA",1130580001.101,1,6,0)136 ^^2^2^3101013^137 "DATA",1130580001.101,1,6,1,0)138 Percentage of patients 18 through 75 years with diabetes melli139 "DATA",1130580001.101,1,6,2,0)140 tus who had most recent hemoglobin A1C greater than 9.0%141 "DATA",1130580001.101,1,7)142 ^^^^143 "DATA",1130580001.101,2,0)144 M5^^^2.16.840.1.113883.3.249.11.5145 "DATA",1130580001.101,2,1)146 CMS Measure #5: Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)147 "DATA",1130580001.101,2,4)148 PQRI-5149 "DATA",1130580001.101,2,5)150 Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)151 "DATA",1130580001.101,2,6,0)152 ^^2^2^3101013^153 "DATA",1130580001.101,2,6,1,0)154 Percentage of patients 18 years and older with a diagnosis of155 "DATA",1130580001.101,2,6,2,0)156 heart failure and LVSD who were prescribed an ACE inhbitor or ARB therapy157 "DATA",1130580001.101,2,7)158 ^^^^159 "DATA",1130580001.101,3,0)160 M112^^^2.16.840.1.113883.3.249.11.9161 "DATA",1130580001.101,3,1)162 Measure #112: Preventive Care and Screening: Screening Mammography163 "DATA",1130580001.101,3,4)164 PQRI-112165 "DATA",1130580001.101,3,5)166 Screening Mammography167 "DATA",1130580001.101,3,6,0)168 ^1130580001.111^2^2^3101014^^169 "DATA",1130580001.101,3,6,1,0)170 Percentage of womaen aged 40 through 69 years who had a mammog171 "DATA",1130580001.101,3,6,2,0)172 ram to screen for breast cancer within 24 months173 "DATA",1130580001.101,3,7)174 ^^^^175 127 "DATA",1130580001.101,4,0) 176 M124^^^2.16.840.1.113883.3.249.11.11128 PQRI MEASURE 124^^^2.16.840.1.113883.3.249.11.11 177 129 "DATA",1130580001.101,4,1) 178 130 Measure #124: Health Information Technology (HIT): Adoption/Use of Electronic Health Records … … 191 143 "DATA",1130580001.101,4,7) 192 144 ^^^^ 193 "DATA",1130580001.101,5,0)194 M128^^^2.16.840.1.113883.3.249.11.54195 "DATA",1130580001.101,5,1)196 Measure #128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up197 "DATA",1130580001.101,5,4)198 PQRI-128199 "DATA",1130580001.101,5,5)200 Body Mass Index (BMI) Screening and Follow-Up201 "DATA",1130580001.101,5,6,0)202 ^1130580001.111^5^5^3101014^^203 "DATA",1130580001.101,5,6,1,0)204 Percentage of patients aged 18 yesrs and older with a calculate BMI in205 "DATA",1130580001.101,5,6,2,0)206 the past 6 months or during the current visit documented in the medical207 "DATA",1130580001.101,5,6,3,0)208 record and if the most recent BMI is ourtide parameters, a follow-up plan209 "DATA",1130580001.101,5,6,4,0)210 is documented. Ages 65 and older BMI equal to or greater than 30 or less211 "DATA",1130580001.101,5,6,5,0)212 than 22 and ages 18-64, BMI greater than or equal to 25 or less than 18.5213 "DATA",1130580001.101,5,7)214 ^^^^215 145 "DATA",1130580001.101,6,0) 216 M47^^^2.16.840.1.113883.3.249.11.52146 PQRI MEASURE 47^^^2.16.840.1.113883.3.249.11.52 217 147 "DATA",1130580001.101,6,1) 218 148 Measure #47: Advance Care Plan … … 236 166 ^^^^ 237 167 "DATA",1130580001.101,7,0) 238 M48^^^2.16.840.1.113883.3.249.11.53168 PQRI MEASURE 48^^^2.16.840.1.113883.3.249.11.53 239 169 "DATA",1130580001.101,7,1) 240 170 Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older … … 253 183 "DATA",1130580001.101,7,7) 254 184 ^^^^ 255 "DATA",1130580001.101,8,0)256 M2^^^2.16.840.1.113883.3.249.11.3257 "DATA",1130580001.101,8,1)258 Measure #2: Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus259 "DATA",1130580001.101,8,4)260 PQRI-2261 "DATA",1130580001.101,8,5)262 Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus263 "DATA",1130580001.101,8,6,0)264 ^^2^2^3101013^265 "DATA",1130580001.101,8,6,1,0)266 Percentage of patients 18 through 75 years with diabetes melli267 "DATA",1130580001.101,8,6,2,0)268 tus who had most recent LDL-C level in control (less than 100 mg./dL)269 "DATA",1130580001.101,8,7)270 ^^^^271 "DATA",1130580001.101,9,0)272 M3^^^2.16.840.1.113883.3.249.11.4273 "DATA",1130580001.101,9,1)274 CMS Measure #3: Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus - QRDA Cat I template275 "DATA",1130580001.101,9,4)276 PQRI-3277 "DATA",1130580001.101,9,5)278 High Blood Pressure Control in Diabetes Mellitus279 "DATA",1130580001.101,9,6,0)280 ^^2^2^3101013^281 "DATA",1130580001.101,9,6,1,0)282 Percentage of patients 18 through 75 years with diabetes melli283 "DATA",1130580001.101,9,6,2,0)284 tus who had most recent blood pressure in control (less than 140/80 mmHg)285 "DATA",1130580001.101,9,7)286 ^^^^287 "DATA",1130580001.101,10,0)288 M7^^^2.16.840.1.113883.3.249.11.6289 "DATA",1130580001.101,10,1)290 CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)291 "DATA",1130580001.101,10,4)292 PQRI-7293 "DATA",1130580001.101,10,5)294 Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy295 "DATA",1130580001.101,10,6,0)296 ^^3^3^3101013^297 "DATA",1130580001.101,10,6,1,0)298 Percentage of patients aged 18 years and older with a diagnosis of299 "DATA",1130580001.101,10,6,2,0)300 coronary artery disease and a prior MI who where prescribed beta-blocker301 "DATA",1130580001.101,10,6,3,0)302 therapy303 "DATA",1130580001.101,10,7)304 ^^^^305 "DATA",1130580001.101,11,0)306 M110^^^2.16.840.1.113883.3.249.11.7307 "DATA",1130580001.101,11,1)308 Measure #110: Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years309 "DATA",1130580001.101,11,4)310 PQRI-110311 "DATA",1130580001.101,11,5)312 Influenza Immunization for Patients >= 50 Years313 "DATA",1130580001.101,11,6,0)314 ^1130580001.111^2^2^3101014^^315 "DATA",1130580001.101,11,6,1,0)316 Percentage of patients aged 50 years and older who received an317 "DATA",1130580001.101,11,6,2,0)318 influenza immunization during the flu season (September through February)319 "DATA",1130580001.101,11,7)320 ^^^^321 185 "DATA",1130580001.101,12,0) 322 M 111^^^2.16.840.1.113883.3.249.11.8186 MU EP NQF 0043^^^2.16.840.1.113883.3.249.11.8 323 187 "DATA",1130580001.101,12,1) 324 188 Measure #111: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older … … 328 192 Pneumonia Vaccination for Patients 65 Years and Older 329 193 "DATA",1130580001.101,12,6,0) 330 ^ ^2^2^3101013^194 ^1130580001.111^2^2^3120730^^ 331 195 "DATA",1130580001.101,12,6,1,0) 332 196 Percentage of patients afed 65 years and older who have ever r 333 197 "DATA",1130580001.101,12,6,2,0) 334 198 eceived a pneumoccal vaccine 335 "DATA",1130580001.101,12,7)336 ^^^^337 "DATA",1130580001.101,13,0)338 M113^^^2.16.840.1.113883.3.249.11.10339 "DATA",1130580001.101,13,1)340 Measure #113: Preventive Care and Screening: Colorectal Cancer Screening341 "DATA",1130580001.101,13,4)342 PQRI-113343 "DATA",1130580001.101,13,5)344 Colorectal Cancer Screening345 "DATA",1130580001.101,13,6,0)346 ^^2^2^3101013^347 "DATA",1130580001.101,13,6,1,0)348 Percentage of patients aged 50 through 80 who received the app349 "DATA",1130580001.101,13,6,2,0)350 ropriate colorectal cancer screening351 "DATA",1130580001.101,13,7)352 ^^^^353 199 "DATA",1130580001.101,14,0) 354 M39^^^2.16.840.1.113883.3.249.11.51200 PQRI MEASURE 39^^^2.16.840.1.113883.3.249.11.51 355 201 "DATA",1130580001.101,14,1) 356 202 Measure #39: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older … … 370 216 ^^^^ 371 217 "DATA",1130580001.101,16,0) 372 M173^^^2.16.840.1.113883.3.249.11.55218 PQRI MEASURE 173^^^2.16.840.1.113883.3.249.11.55 373 219 "DATA",1130580001.101,16,1) 374 220 Measure #173: Preventive Care and Screening: Unhealthy Alcohol Use - Screening … … 384 230 ed for unhealthy alcohol use using a systematic method within 24 months 385 231 "DATA",1130580001.101,16,7) 386 ^^^^387 "DATA",1130580001.101,17,0)388 M0013^^^2.16.840.1.113883.3.249.11.56389 "DATA",1130580001.101,17,1)390 Measure #0013: Hypertension (HTN): Blood Pressure Measurement - QRDA Cat I template391 "DATA",1130580001.101,17,4)392 PQRI-13393 "DATA",1130580001.101,17,5)394 Hypertension (HTN): Blood Pressure Measurement395 "DATA",1130580001.101,17,6,0)396 ^1130580001.111^3^3^3110412^^397 "DATA",1130580001.101,17,6,1,0)398 Percentage of patients aged 18 years and older with a diagnosi399 "DATA",1130580001.101,17,6,2,0)400 s of hypertension in the beginning of the measurement period with a blood401 "DATA",1130580001.101,17,6,3,0)402 pressure recorded403 "DATA",1130580001.101,17,7)404 ^^^^405 "DATA",1130580001.101,18,0)406 M0022^^^2.16.840.1.113883.3.249.11.57407 "DATA",1130580001.101,18,1)408 Measure #0022: Drugs to be avoided in the Elderly409 "DATA",1130580001.101,18,4)410 PQRI-22411 "DATA",1130580001.101,18,5)412 Drugs to be avoided in the elderly413 "DATA",1130580001.101,18,6,0)414 ^^2^2^3101013^415 "DATA",1130580001.101,18,6,1,0)416 Percentage of patients aged 65 years and older who received at least one417 "DATA",1130580001.101,18,6,2,0)418 drug to be avoided in the elderly in the measurement period419 "DATA",1130580001.101,18,7)420 ^^^^421 "DATA",1130580001.101,19,0)422 M0028^^^2.16.840.1.113883.3.249.11.59423 "DATA",1130580001.101,19,1)424 Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention425 "DATA",1130580001.101,19,4)426 PQRI-28427 "DATA",1130580001.101,19,5)428 Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention429 "DATA",1130580001.101,19,6,0)430 ^^4^4^3101013^431 "DATA",1130580001.101,19,6,1,0)432 Percentage of patients aged 18 years of older who were screene433 "DATA",1130580001.101,19,6,2,0)434 d about tobacco use at least once during the two year measurement period435 "DATA",1130580001.101,19,6,3,0)436 AND who received smoking cessation counseling if identified as a tobacco437 "DATA",1130580001.101,19,6,4,0)438 user439 "DATA",1130580001.101,19,7)440 ^^^^441 "DATA",1130580001.101,20,0)442 M0038^^^2.16.840.1.113883.3.249.11.60443 "DATA",1130580001.101,20,1)444 Measure #0038: Childhood Immunization Status445 "DATA",1130580001.101,20,4)446 PQRI-38447 "DATA",1130580001.101,20,5)448 Childhood immumnization status449 "DATA",1130580001.101,20,6,0)450 ^^4^4^3101013^451 "DATA",1130580001.101,20,6,1,0)452 Percentage of children who turn two years of age during the me453 "DATA",1130580001.101,20,6,2,0)454 asurement period who have had 4 DTaP/DT, 3 IPV, 1 MMR and 3 H influenza455 "DATA",1130580001.101,20,6,3,0)456 type B, 3 hepatitis B, 1 chicken pox vaccine (VZV) and 4 pneumoccal457 "DATA",1130580001.101,20,6,4,0)458 conjugate vaccines by their second birthday459 "DATA",1130580001.101,20,7)460 ^^^^461 "DATA",1130580001.101,21,0)462 M0024^^463 "DATA",1130580001.101,21,7)464 ^^^^465 "DATA",1130580001.101,22,0)466 TEST M0028A^^^2.16.840.1.113883.3.249.11.59467 "DATA",1130580001.101,22,1)468 Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention469 "DATA",1130580001.101,22,4)470 PQRI-28471 "DATA",1130580001.101,22,5)472 Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention473 "DATA",1130580001.101,22,6,0)474 ^1130580001.111^4^4^3110427^^^^475 "DATA",1130580001.101,22,6,1,0)476 Percentage of patients aged 18 years of older who were screene477 "DATA",1130580001.101,22,6,2,0)478 d about tobacco use at least once during the two year measurement period479 "DATA",1130580001.101,22,6,3,0)480 AND who received smoking cessation counseling if identified as a tobacco481 "DATA",1130580001.101,22,6,4,0)482 user483 "DATA",1130580001.101,22,7)484 232 ^^^^ 485 233 "DATA",1130580001.101,23,0) … … 767 515 "DATA",1130580001.101,37,7) 768 516 NQF0376^^^^^^158^162 769 "DATA",1130580001.101,38,0)770 12^^771 "DATA",1130580001.101,38,7)772 ^^^^773 517 "DATA",1130580001.101,39,0) 774 MU EP NQF 0421^^ 518 MU EP NQF 0421^^^2.16.840.1.113883.3.249.11.54 775 519 "DATA",1130580001.101,39,1) 776 520 NQF0421 Adult Weight Screening and Follow-Up 521 "DATA",1130580001.101,39,4) 522 PQRI-128 777 523 "DATA",1130580001.101,39,5) 778 524 NQF0421 Adult Weight Screening and Follow-Up … … 794 540 NQF0421^^^^^^321^320^10 795 541 "DATA",1130580001.101,40,0) 796 MU EP NQF 0013^^ 542 MU EP NQF 0013^^^2.16.840.1.113883.3.249.11.56 797 543 "DATA",1130580001.101,40,1) 798 544 NQF0013 Hypertension: Blood Pressure Measurement 545 "DATA",1130580001.101,40,4) 546 PQRI-13 799 547 "DATA",1130580001.101,40,5) 800 548 NQF0013 Hypertension: Blood Pressure Measurement 801 549 "DATA",1130580001.101,40,6,0) 802 ^1130580001.111^4^4^31 20712^^^550 ^1130580001.111^4^4^3110628^^ 803 551 "DATA",1130580001.101,40,6,1,0) 804 552 Percentage of patient visits for patients … … 812 560 NQF0013^^^^^^142^167 813 561 "DATA",1130580001.101,41,0) 814 MU EP NQF 0028A^^ 562 MU EP NQF 0028A^^^2.16.840.1.113883.3.249.11.59 815 563 "DATA",1130580001.101,41,1) 816 564 NQF0028A Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention 565 "DATA",1130580001.101,41,4) 566 PQRI-28 817 567 "DATA",1130580001.101,41,5) 818 568 NQF0028A Tobacco Use Assessment … … 836 586 NQF0028A^^^^^^157^160 837 587 "DATA",1130580001.101,42,0) 838 MU EP NQF 0041^^ 588 MU EP NQF 0041^^^2.16.840.1.113883.3.249.11.7 839 589 "DATA",1130580001.101,42,1) 840 590 Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old 591 "DATA",1130580001.101,42,4) 592 PQRI-110 841 593 "DATA",1130580001.101,42,5) 842 594 NQF0041 Influenza Immunization 50 years and older … … 860 612 NQF0024 Weight Assessment and Counseling for Children and Adolescents 861 613 "DATA",1130580001.101,43,6,0) 862 ^ 1130580001.111^6^6^3120713^^614 ^^6^6^3110430^ 863 615 "DATA",1130580001.101,43,6,1,0) 864 616 Percentage of patients 2 -17 years of age … … 876 628 NQF0024^^^^^^151^149 877 629 "DATA",1130580001.101,44,0) 878 MU EP NQF 0038^^ 630 MU EP NQF 0038^^^2.16.840.1.113883.3.249.11.60 879 631 "DATA",1130580001.101,44,1) 880 632 Childhood Immunization Status 633 "DATA",1130580001.101,44,4) 634 PQRI-38 881 635 "DATA",1130580001.101,44,5) 882 636 Childhood Immunization Status … … 914 668 NQF0038^^^^ 915 669 "DATA",1130580001.101,45,0) 916 MU EP NQF 0059^^ 670 MU EP NQF 0059^^^2.16.840.1.113883.3.249.11.2 917 671 "DATA",1130580001.101,45,1) 918 672 Diabetes: Hemoglobin A1c Poor Contro 673 "DATA",1130580001.101,45,4) 674 PQRI-1 919 675 "DATA",1130580001.101,45,5) 920 676 Diabetes: NQF0059 Hemoglobin A1c Poor Control 921 677 "DATA",1130580001.101,45,6,0) 922 ^ 1130580001.111^2^2^3120716^^678 ^^2^2^3110430^ 923 679 "DATA",1130580001.101,45,6,1,0) 924 680 Percentage of patients 18 - 75 years of age with diabetes (type 1 … … 928 684 NQF0059^^^^^^260^258 929 685 "DATA",1130580001.101,46,0) 930 MU EP NQF 0064^^ 686 MU EP NQF 0064^^^2.16.840.1.113883.3.249.11.3 931 687 "DATA",1130580001.101,46,1) 932 688 Diabetes: Low Density Lipoprotein (LDL) Management and Control 689 "DATA",1130580001.101,46,4) 690 PQRI-2 933 691 "DATA",1130580001.101,46,5) 934 692 NQF0064 Diabetes: Low Density Lipoprotein (LDL) Management and Control … … 944 702 NQF0064^^^^^^248^258 945 703 "DATA",1130580001.101,47,0) 946 MU EP NQF 0061^^ 704 MU EP NQF 0061^^^2.16.840.1.113883.3.249.11.4 947 705 "DATA",1130580001.101,47,1) 948 706 Blood Pressure Management 707 "DATA",1130580001.101,47,4) 708 PQRI-3 949 709 "DATA",1130580001.101,47,5) 950 710 NQF0061 Diabetes: Blood Pressure Management … … 958 718 NQF0061^^^^^^262^258 959 719 "DATA",1130580001.101,48,0) 960 MU EP NQF 0081^^ 720 MU EP NQF 0081^^^2.16.840.1.113883.3.249.11.5 961 721 "DATA",1130580001.101,48,1) 962 722 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) 723 "DATA",1130580001.101,48,4) 724 PQRI-5 963 725 "DATA",1130580001.101,48,5) 964 726 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) … … 974 736 NQF0081^^^^ 975 737 "DATA",1130580001.101,49,0) 976 MU EP NQF 0070^^ 738 MU EP NQF 0070^^^2.16.840.1.113883.3.249.11.6 977 739 "DATA",1130580001.101,49,1) 978 Pneumonia Vaccination Status for Older Adults 740 CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) 741 "DATA",1130580001.101,49,4) 742 PQRI-7 979 743 "DATA",1130580001.101,49,5) 980 P neumonia Vaccination Status for Older Adults744 Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy 981 745 "DATA",1130580001.101,49,6,0) 982 ^^ 2^2^3110430^746 ^^3^3^3101013^ 983 747 "DATA",1130580001.101,49,6,1,0) 984 Percentage of patients 65 years of age and older who have ever748 Percentage of patients aged 18 years and older with a diagnosis of 985 749 "DATA",1130580001.101,49,6,2,0) 986 received a pneumococcal vaccine. 750 coronary artery disease and a prior MI who where prescribed beta-blocker 751 "DATA",1130580001.101,49,6,3,0) 752 therapy 987 753 "DATA",1130580001.101,49,7) 988 NQF0070 ^^^^754 NQF0070 989 755 "DATA",1130580001.101,50,0) 990 MU EP NQF 0031^^ 756 MU EP NQF 0031^^^2.16.840.1.113883.3.249.11.9 991 757 "DATA",1130580001.101,50,1) 992 758 Breast Cancer Screening 759 "DATA",1130580001.101,50,4) 760 PQRI-112 993 761 "DATA",1130580001.101,50,5) 994 762 Breast Cancer Screening … … 1002 770 NQF0031^^^^ 1003 771 "DATA",1130580001.101,51,0) 1004 MU EP NQF 0034^^ 772 MU EP NQF 0034^^^2.16.840.1.113883.3.249.11.10 1005 773 "DATA",1130580001.101,51,1) 1006 774 Colorectal Cancer Screening 775 "DATA",1130580001.101,51,4) 776 PQRI-113 1007 777 "DATA",1130580001.101,51,5) 1008 778 Colorectal Cancer Screening … … 1571 1341 "DATA",1130580001.101,81,7) 1572 1342 NQF0028B^^^^^^154^160 1573 "DATA",1130580001.101,82,0)1574 MU EP 0028B^^1575 "DATA",1130580001.101,82,7)1576 ^^^^1577 1343 "DATA",1130580001.101,83,0) 1578 NQF0038 NUM1 DPT^^1344 MU EP NQF 0038 NUM1 DPT^^ 1579 1345 "DATA",1130580001.101,83,5) 1580 1346 NQF0038 NUM1 DPT … … 1582 1348 NQF0038 NUM1 DPT^^^^^^329^192^11 1583 1349 "DATA",1130580001.101,84,0) 1584 NQF0038 NUM2 IPV^^1350 MU EP NQF 0038 NUM2 IPV^^ 1585 1351 "DATA",1130580001.101,84,5) 1586 1352 NQF0038 NUM2 IPV … … 1588 1354 NQF0038 NUM2 IPV^^^^^^224^192^11 1589 1355 "DATA",1130580001.101,85,0) 1590 NQF0038 NUM3 MMR^^1356 MU EP NQF 0038 NUM3 MMR^^ 1591 1357 "DATA",1130580001.101,85,5) 1592 1358 NQF0038 NUM3 MMR … … 1594 1360 NQF0038 NUM3 MMR^^^^^^183^192^11 1595 1361 "DATA",1130580001.101,86,0) 1596 NQF0038 NUM4 HiB^^1362 MU EP NQF 0038 NUM4 HiB^^ 1597 1363 "DATA",1130580001.101,86,5) 1598 1364 NQF0038 NUM4 HiB … … 1600 1366 NQF0038 NUM4 HiB^^^^^^189^192^11 1601 1367 "DATA",1130580001.101,87,0) 1602 NQF0038 NUM5 HEP B^^1368 MU EP NQF 0038 NUM5 HEP B^^ 1603 1369 "DATA",1130580001.101,87,5) 1604 1370 NQF0038 NUM5 HEP B … … 1606 1372 NQF0038 NUM5 HEP B^^^^^^194^192^11 1607 1373 "DATA",1130580001.101,88,0) 1608 NQF0038 NUM6 VZV^^1374 MU EP NQF 0038 NUM6 VZV^^ 1609 1375 "DATA",1130580001.101,88,5) 1610 1376 NQF0038 NUM6 VZV … … 1612 1378 NQF0038 NUM6 VZV^^^^^^198^192^11 1613 1379 "DATA",1130580001.101,89,0) 1614 NQF0038 NUM7 PCV^^1380 MU EP NQF 0038 NUM7 PCV^^ 1615 1381 "DATA",1130580001.101,89,5) 1616 1382 NQF0038 NUM7 PCV … … 1618 1384 NQF0038 NUM7 PCV^^^^^^205^192^11 1619 1385 "DATA",1130580001.101,90,0) 1620 NQF0038 NUM8 HEP A^^1386 MU EP NQF 0038 NUM8 HEP A^^ 1621 1387 "DATA",1130580001.101,90,5) 1622 1388 NQF0038 NUM8 HEP A … … 1624 1390 NQF0038 NUM8 HEP A^^^^^^208^192^11 1625 1391 "DATA",1130580001.101,91,0) 1626 NQF0038 NUM9^^1392 MU EP NQF 0038 NUM9 RV^^ 1627 1393 "DATA",1130580001.101,91,5) 1628 1394 NQF0038 NUM9 … … 1630 1396 NQF0038 NUM9^^^^^^216^192^11 1631 1397 "DATA",1130580001.101,92,0) 1632 NQF0038 NUM10^^1398 MU EP NQF 0038 NUM10 FLU^^ 1633 1399 "DATA",1130580001.101,92,5) 1634 1400 NQF0038 NUM10 … … 1636 1402 NQF0038 NUM10^^^^^^331^192^11 1637 1403 "DATA",1130580001.101,93,0) 1638 NQF0038 NUM11 COMBO5^^1404 MU EP NQF 0038 NUM11 COMBO5^^ 1639 1405 "DATA",1130580001.101,93,5) 1640 1406 NQF0038 NUM11 COMBO5 … … 1642 1408 NQF0038 NUM11 COMBO5^^^^^^228^192^11 1643 1409 "DATA",1130580001.101,94,0) 1644 NQF0038 NUM12 COMBO6^^1410 MU EP NQF 0038 NUM12 COMBO6^^ 1645 1411 "DATA",1130580001.101,94,5) 1646 1412 NQF0038 NUM12 COMBO6 … … 2442 2208 ^9.49I^1^1 2443 2209 "PKG",215,22,1,0) 2444 1.0^31207 13^3120702^82210 1.0^3120731^3120802^8 2445 2211 "PKG",215,22,1,"PAH",1,0) 2446 3^3120 7272212 3^3120803 2447 2213 "PKG",215,22,1,"PAH",1,1,0) 2448 ^^5^5^3120 7272214 ^^5^5^3120803 2449 2215 "PKG",215,22,1,"PAH",1,1,1,0) 2450 2216 Created by Sam Habiel on July 13th 2012 for distribution with WorldVistA … … 2544 2310 8.0^22.0 2545 2311 "^DD",1130580001.101,1130580001.101,0) 2546 FIELD^^ 2.5^182312 FIELD^^.3^18 2547 2313 "^DD",1130580001.101,1130580001.101,0,"DDA") 2548 2314 N 2549 2315 "^DD",1130580001.101,1130580001.101,0,"DT") 2550 31 207262316 3111201 2551 2317 "^DD",1130580001.101,1130580001.101,0,"ID",.7) 2552 2318 W:$D(^(5)) " ",$P(^(5),U,1)
Note:
See TracChangeset
for help on using the changeset viewer.
